Emily Bodnar’s score relies over the anticipation of considerable milestones for Agenus in the coming calendar year, specifically the opportunity filing of the Biologics License Software (BLA) for their lead drug applicant, botensilimab (bot). Agenus has dosed around 900 people with bot throughout numerous sound tumors, exhibiting a dedication to